CA-GRINDR
At the outset of European testing week, Grindr Inc. (NYSE: GRND), the world’s largest social network for the LGBTQ+ community, today announced the launch of its new partnerships with Equality Movement and MPOWER to connect Grindr users directly with HIV self-test kits in Georgia and Ireland, respectively. With these partnerships, Georgia and Ireland become the first countries outside of the United States in which Grindr users can order free at-home HIV self-test kits directly from links embedded in the Grindr interface, in less than one minute.
Access to HIV testing continues to be one of the biggest obstacles in the fight against the global HIV epidemic. In-person testing, in particular, poses barriers such as clinic operating hours, transportation, costs, and concerns about privacy or stigma. These barriers become even more pronounced for a variety of Grindr users, such as those living in rural areas, or those who are not “out” to their families. At-home self-testing offers users a convenient and discrete option to protect their health.
Grindr has a long history of promoting both Equality Movement and MPOWER’s home self-testing programs. As it became clear that a significant number of Grindr users needed the level of flexibility and anonymity that home self-testing provides, Grindr decided to partner with both organizations to make this easier than ever. In expanding this collaboration, Grindr emphasizes both organizations’ commitment to implementing community-level interventions and judgment-free resources.
“For the past eight years, it has been my goal to find ways to increase access to HIV testing for Grindr users, and of all the things we’ve experimented with, embedding in-app links to home self-test kits has emerged as the most powerful strategy by a considerable margin,” said Jack Harrison-Quintana, Director of Grindr For Equality. “I could not be more excited to launch partnerships similar to those with Equality Movement and MPOWER around the world.”
“Making free at-home HIV self-testing available directly through the Grindr app helps to ensure members of the LGBTQ+ community have access to vital services they need to protect their health and feel supported in their daily lives,” said Lasha Nonikashvili at Equality Movement. “We are thrilled that the LGBTQ+ community across Georgia will now be able to protect their health with an easy solution they can access from home.”
“This partnership with Grindr has the potential to revolutionize the way our community across Ireland accesses vital at-home HIV self-testing,” said Adam Shanley at MPOWER, whose mission is to devise sex-positive, judgment-free and harm reduction-based resources, services and support for gay, bisexual and MSM in Ireland. “By making these resources more widely available at home, we hope to increase access, reduce stigma, and contribute to the long-term reduction of HIV.”
Today’s announcement builds on Grindr’s commitment to achieving a meaningful impact for the LGBTQ+ community. Earlier this year, we partnered with Building Healthy Online Communities and Emory University to launch Together TakeMeHome (TTMH) with support from the U.S. Centers for Disease Control and Prevention. TTMH is a unique partnership that has distributed over 232,262 test kits within the first six months of the program. Nearly a quarter of those orders were placed by people who had never previously tested for HIV, and a majority were requested through Grindr. Grindr remains committed to launching similar programs for users around the world.
About Grindr Inc.
With more than 13 million monthly active users in virtually every country in the world, Grindr has grown to become a fundamental part of the LGBTQ+ community since its launch in 2009. The company continues to expand its ecosystem to enable gay, bi, trans, and queer people to connect, express themselves, and discover the world around them. Grindr’s impact is further driven by Grindr for Equality’s wide-ranging initiatives that help the LGBTQ+ community around the world. Grindr is headquartered in West Hollywood, California. The Grindr app is available on the App Store and Google Play.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120646279/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges23.6.2025 14:05:00 CEST | Press release
As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623205345/en/ LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech’s analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highli
Sagemcom’s Net Zero Trajectory Approved by SBTi: Target Set for 204023.6.2025 14:00:00 CEST | Press release
Sagemcom Group has today reached a critical milestone in its climate strategy: its Net Zero carbon target for 2040—encompassing all activities and sites within the Group’s consolidated scope—has been officially validated by the Science Based Targets initiative (SBTi). This international endorsement attests to the scientific rigor of Sagemcom’s decarbonization strategy, aligned with the Paris Agreement’s ambition to limit global warming to 1.5°C. It strengthens the Group’s comprehensive climate roadmap, which is built on a significant reduction of greenhouse gas emissions across all scopes: By 2030: A 47% absolute reduction in Scope 1 and Scope 2 emissions (direct emissions and purchased energy), 100% renewable energy consumption across all Group sites, A 31% absolute reduction in Scope 3 emissions, including those related to the value chain, with no exclusion of any greenhouse gas categories. By 2040: Achievement of Net Zero, corresponding to a 90% absolute reduction in total Group emi
One, Two, Three-Peat: Mary Kay Inc. Named #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World for Three Years in a Row23.6.2025 14:00:00 CEST | Press release
Good things come in threes: iconic beauty brand and global entrepreneurship company Mary Kay Inc. has again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World1 by Euromonitor International for the third consecutive year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623000452/en/ Ryan Rogers, Chief Executive Officer of Mary Kay states: "Being named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International three years in a row marks a grand slam achievement for Mary Kay. This repeated milestone reflects years of R&D and marketing efforts to create skin and beauty solutions that meet consumer needs and are loved the world-over. Above all, it demonstrates the transformative power of our Independent Beauty Consultants who are driving this success globally." (Photo Courtesy: Mary Kay Inc.) Euromonitor International is the foremost provider of globa
Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries23.6.2025 13:00:00 CEST | Press release
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter “Plasma Services Group”). The transaction value has not been disclosed. Founded in 2004, Plasma Services Group has specialized in the collection, screening and supply of high quality and rare biological materials required for R&D and manufacturing in the in vitro diagnostics (IVD) and life science industries. The company is particularly well positioned in the field of rare diseases. From its state-of-the-art FDA registered, ISO certified facility in Moorestown, NJ, USA, Plasma Services Group provides sera and other samples for materials of control reagents and calibrators for a wide range of diseases and offers sample collection services globally. For more information about Plasma Services Group please visit www.plasmaservicesgroup.com
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression23.6.2025 12:30:00 CEST | Press release
A single administration of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS1 with a mean difference of -3.6 comparing 25 mg to placebo (p<0.001)2Independent Data Safety Monitoring Board (DSMB) reviewed safety data for COMP360 and found no unexpected safety findings and no clinically meaningful imbalance in suicidal ideation between treatment and placebo armsOngoing pivotal Phase 3 COMP005 trial is the first study of an investigational, synthetic psilocybin, and the first classic psychedelic3, to report Phase 3 efficacy dataSecond ongoing pivotal Phase 3 COMP006 trial continues to enroll well, with 26-week data expected in the second half of 2026 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom